gutflix
GI learning, personalised

Summary

A TRANSCRIPTOME-DEPENDENT PROGNOSTIC MODEL OF RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS

Catherine Milch

UEG Week Copenhagen 2023 | Poster

IBD

October 16, 2023

A transcriptomic model using baseline gene expression predicted clinical response to mirikizumab 200mg in ulcerative colitis patients with high accuracy in the phase 2 AMAC trial.

KEY POINTS

- In the phase 2 AMAC trial, 59.7% of patients treated with mirikizumab 200mg achieved clinical response compared to 20.6% with placebo, as measured by reduction in 9-point Mayo subscore.
- Baseline colonic biopsy gene expression analysis identified 84 differentially expressed genes maintaining expression through Week 52 in mirikizumab 200mg responders and 26 in placebo responders, with 21 genes common to both.
- An XGBoost predictive model trained on PROTECT trial data and validated in AMAC achieved high performance using the top 36 mirikizumab-associated genes (PR-AUC=0.78) or combined gene sets (PR-AUC=0.93), significantly distinguishing responders from non-responders.
- Validation studies are planned to confirm whether baseline transcriptomic profiling can prospectively identify ulcerative colitis patients likely to respond to mirikizumab treatment.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/ae812a28-743c-11ee-8c8c-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.